Susan J. Hayflick, M.D.
Professor & Chair
Molecular & Medical Genetics
Professor, Pediatrics and Neurology
Oregon Health & Science University
Susan Hayflick is a medical doctor and professor as well as Chairman of the Department of Molecular & Medical Genetics at the Oregon Health & Science University in Portland. She also is a professor of pediatrics and neurology.
Dr. Hayflick has been studying NBIA since 1991. Her lab, working with the labs of collaborators discovered the NBIA genes, PANK2, PLA2G6, FA2H, and WDR45. Her research is focused on gaining sufficient understanding of the NBIA disease process to enable the development and testing of new therapies.
The Hayflick lab has received research support from the NBIA Disorders Association, the NIH (NEI, NINDS & NICHD), the Association Internationale de Dystrophie Neuro Axonale Infantile, the Associazione Italiana Sindromi Neurodegenerativi da Accumulo di Ferro, the European Commission, as well as from numerous families from around the world. Hayflick has authored numerous articles about NBIA. She also provides clinical consultation to families and physicians around the world who are caring for people with NBIA.
Penny Hogarth, M.D.
Associate Professor of Neurology and Molecular & Medical Genetics
Oregon Health & Science University
Penelope Hogarth, MD, is a neurologist and associate professor at Oregon Health & Science University. She completed medical school and residency training at the University of Colorado. After completing a fellowship in movement disorders and clinical research trial design at the University of Rochester in New York, she relocated to Portland, Oregon. In addition to studying NBIA and PKAN, her research interests extend to Huntington’s disease, Parkinson’s disease, and dystonia. Dr. Hogarth follows adult patients undergoing deep brain stimulation and is an investigator in national studies of Parkinson’s disease and other movement disorders.
Paul T. Kotzbauer, M.D., Ph.D.
Asst. Professor, Dept. of Neurology
Washington University School of Medicine
St. Louis, Missouri
Paul T. Kotzbauer, MD, PhD, is an assistant professor in the Department of Neurology at Washington University School of Medicine in St. Louis, Missouri, where he completed medical school and earned his doctorate in neuroscience. He received further training in neurology and movement disorders at the University of Pennsylvania. Kotzbauer sees patients in the Movement Disorders Center at Washington University, and his research focuses on Parkinson’s disease and NBIA.
Steven P. Richieri
Senior Vice President
Banyan Biomarkers, Inc.
Steven P. Richieri is currently a Senior Vice President for Banyan Biomarkers, Inc., a start-up medical device company which is a leader in developing in vitro diagnostic products for the detection of traumatic brain injury (TBI). Richieri is a senior executive with strong start-up and biomedical company experience. He has more than 25 years of experience in the health care industry, and has a broad background in biotechnology, pharmaceutical and medical device product development and research.
Richieri also has extensive experience in the US Food and Drug Administration’s regulatory process and has been responsible for taking a number of products from the research laboratory to the clinic for stroke, HIV, autoimmune diseases, cancer, and allergic rhinitis.
LuAmy Sun MD, PhD, FACP
Director, siRNA Therapeutics
Merck & Co., Inc.
North Whales, PA
Dr. Sun, a Fellow of the American College of Physicians, is Board certified in Internal Medicine with specialty training in Endocrinology and Clinical Pharmacology, and with a Ph.D. in Molecular Pharmacology. Sun has extensive experience in managing both early and later phase global clinical trials, clinical safety and post marketing pharmacovigilance across therapeutic areas, including endocrinology, oncology, women’s health care and cardiovascular diseases. She has contributed to numerous NDAs, INDs, and global regulatory submissions, which lead to the market launch of a number of therapeutic agents.
As director of Clinical Risk Management at Merck, Sun is responsible for the overall safety of oncology compounds the company is developing or marketed. She is skilled in leading matrix Risk Management Strategic Teams, applying FDA/ICH guidelines for clinical evaluation of drug safety, working with Medical Affairs in supporting product scientific and business strategy, and responding to worldwide regulatory inquiries.
Sun has diverse work experiences. She has worked in an academic institution, federal government organization, consumer product company and private practice. She brings to the NBIA organization experiences in molecular pharmacology and drug development.